[go: up one dir, main page]

WO2003013588A1 - Materiau de regeneration de rein comprenant des cellules et un facteur de croissance cellulaire - Google Patents

Materiau de regeneration de rein comprenant des cellules et un facteur de croissance cellulaire Download PDF

Info

Publication number
WO2003013588A1
WO2003013588A1 PCT/JP2002/007995 JP0207995W WO03013588A1 WO 2003013588 A1 WO2003013588 A1 WO 2003013588A1 JP 0207995 W JP0207995 W JP 0207995W WO 03013588 A1 WO03013588 A1 WO 03013588A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell growth
kidney
growth factor
regeneration
Prior art date
Application number
PCT/JP2002/007995
Other languages
English (en)
Japanese (ja)
Inventor
Yasuhiko Tabata
Osamu Ogawa
Original Assignee
Kaken Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co., Ltd. filed Critical Kaken Pharmaceutical Co., Ltd.
Priority to JP2003518592A priority Critical patent/JP4358621B2/ja
Publication of WO2003013588A1 publication Critical patent/WO2003013588A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/26—Materials or treatment for tissue regeneration for kidney reconstruction

Definitions

  • the present invention relates to a material for regenerating kidney in vivo, characterized by using a combination of undifferentiated mesenchymal stem cells and a cell growth factor.
  • Reconstructive medicine using artificial organs is currently making significant contributions to the clinic, but has the major drawback of being temporary, invasive, and having a single function that can be supported.
  • transplantation medicine has problems such as infections and carcinogenesis due to side effects of immunosuppressive drugs after transplantation, in addition to the shortage of donors. In this way, the current two pillars of advanced medicine have reached their limits. Under such circumstances, a new treatment attempt is being made to restore a defective or threatened tissue or organ by regenerating its own tissue. This is regenerative medicine. It is an attempt to artificially reestablish one's own tissues and organs by using the.
  • a scaffold for regeneration is required.
  • the biological tissue at the regeneration site can serve as a scaffold for regeneration, but there are also cases where a scaffold Matritta is required as a scaffold for regeneration.
  • Bioabsorbable materials are used as this matrix.
  • these factors have a short in vivo life span and are unstable, and the expected tissue regeneration effect cannot be obtained simply by dissolving the necessary cell growth factor in water and injecting it into the required site. Therefore, the concentration of cell growth factor at the regeneration site must be kept at an effective value for the required period.
  • it is a technology that does not contain cell growth factors in a sustained-release carrier and releases them continuously in the field of regeneration. Sustained release of cell growth factors enhances cell proliferation and differentiation, and promotes self-organization regeneration.
  • regeneration with cell growth factors alone is often insufficient.
  • the kidney is a blood filtration organ that excretes the end products of body metabolism in the form of urine and regulates the concentration of hydrogen, sodium, potassium, phosphorus and other ions in the extracellular fluid. Depending on the balance between excretion and reabsorption mechanism, it has functions such as regulation of water, electrolyte, fluid osmotic pressure, and acid-base balance.
  • kidney function fails, blood pressure increases, nitrogen metabolites such as urea and creatine accumulate in the blood, and blood levels of biowaste increase to harmful levels. In order to eliminate such pathology, it is necessary to replace the function of the failing kidney.
  • Hemodialysis is a procedure that cleans and filters blood that is in renal failure. This measure reduces the concentration of hazardous waste. However, this treatment It takes 3-4 times a week, 2-4 hours once a week, and there are problems of side effects and complications.
  • Kidney transplantation is a procedure in which a healthy kidney from a donor is implanted in an individual suffering from renal failure.
  • lifelong administration of immunosuppressive drugs is required, and the resulting side effects such as infectivity and canceration are problematic.
  • Another problem is that there is not a sufficient amount of donors for all individuals requiring transplantation.
  • kidney cells instead of transplanting the kidney itself, transplantation of kidney cells has also been reported (Pediatrics, 1996, 98S, 615). According to it, C 5 7 black mouse kidney cells were cultured, encapsulated in a polycarbonate tube, and transplanted subcutaneously in an athymic mouse. In the observation up to 8 weeks later, angiogenesis, glomeruli and urine 'tubules' A similar structure was observed. Alkaline phosphatase and fibronectin were found in the tubule-like structure, and uric acid was detected from the secreted yellow liquid.
  • WO 9 8/0 9 5 8 2 discloses an artificial kidney to which the above technique is applied.
  • this artificial kidney is a hybrid type artificial kidney, that is, a kidney that has been removed, cultured, and then reconstructed into an organ.
  • Such differentiated cells have a limited life span, and it is difficult to maintain their function as kidney cells, so there are problems with the durability and reliability of the artificial kidney.
  • non-self cells such as from different animals, there is always a problem of immune rejection.
  • the present invention provides a material for regenerating the kidney in vivo by using a combination of undifferentiated mesenchymal stem cells and cell growth factors.
  • the present invention also relates to a method for regenerating a kidney, comprising using the above material.
  • a group of collagen sponges containing undifferentiated mesenchymal stem cells and bFGF-impregnated gelatin particles A: X 1 0 0, B: X 4 0 0, arrows indicate regenerated glomeruli (embedding
  • Collagen sponge embedded group containing undifferentiated mesenchymal stem cells A: X 1 0 0, B: X
  • the cells used in the present invention are undifferentiated mesenchymal stem cells. These cells can be collected from animals or humans, or the number of collected cells can be increased in culture. Can.
  • the undifferentiated mesenchymal stem cells used in the present invention, their mixing with cell growth factors, and regeneration of kidney tissue using these tissue engineering materials can be performed by the following methods. Although some modification points can be added to cell isolation methods, they do not contribute significantly to the differentiation properties of cells.
  • the method for collecting undifferentiated mesenchymal stem cells can be performed by a conventional method. For example, bone marrow fluid is collected from bone marrow such as femur and osteoid, and the cells are dispersed by pipetting or the like, suspended in an appropriate medium or saline such as ⁇ -MEM, and the bone marrow cell suspension is obtained. Prepare. The cells are cultured in an incubator under conditions of 37 ° C and 5% carbon dioxide, for example, for 7 to 10 days, and then the adherent cells are detached using, for example, 0.05% trypsin and collected. To do.
  • the obtained undifferentiated mesenchymal stem cells can be cultured in an incubator under conditions of 37 ° C and 5% carbon dioxide gas, and the cells can be proliferated and subcultured. Disperse these cells in the culture medium and mix them with appropriate concentrations of cell growth factors.
  • the resulting complex is implanted, for example, in a SD rat kidney defect. After 36 weeks, regeneration of renal tissue is seen at the site of implantation.
  • any tissue can be used in the present invention regardless of the kind of animal to be collected, age, and site thereof.
  • immune rejection is a biological response to cellular components.
  • a method for avoiding this immune rejection for example, there is a method using undifferentiated mesenchymal stem cells collected from its own tissue. According to this, it is considered that the problem of immune reaction can be solved.
  • the self-renal tissue can be regenerated by utilizing the self-cell component.
  • the cell growth factor used in the present invention is not particularly limited, but preferably has a function of increasing the number of undifferentiated mesenchymal stem cells.
  • basic fibroblast growth factor b FGF
  • platelet-derived growth factor PDGF
  • insulin insulin-like growth factor
  • I GF insulin-like growth factor
  • HGF hepatocyte growth factor
  • GDNF glia-induced neurotrophic factor
  • NF Neurotrophic factor
  • BMP bone morphogenetic factor
  • TGF transforming growth factor
  • bFGF is particularly desirable. Its concentration is the number of cells Per 10 5 to 10 8 pieces, 0.0 0:! To 1 0 / g, preferably 0.0 1 to 1.
  • sustained release period should be in the range of about 1 to 3 weeks.
  • the carrier for sustained release of cell growth factor is preferably one having the property of being decomposed and absorbed in vivo.
  • polylactic acid, polyglycolic acid, copolymer of lactic acid and dalcholic acid, poly-f-force prolatatone, f-copolymer of force prolatatone and lactic acid or glycolic acid polyquenic acid, polymalic acid, poly 1 ⁇ -cyanoacrylate, poly 1j3-hydroxybutyrate, polytrimethylene oxalate, poly tramethylene oxalate, polyorthoester, polyorthocarbonate, polyethylene carbonate, polypropylene carbonate, poly 1 ⁇ -benzen ⁇ Synthetic polymers such as L-glutamate, poly- ⁇ -methyl-L-glutamate, poly-l-alanine, polysaccharides such as starch, alginic acid, hyaluronic acid, chitin, pectinic acid and their derivatives, gelatin, collagen ( Collagen (
  • Carriers for sustained release of cell growth factors can be prepared from these materials, but the forms include, but are not limited to, discs, films, rods, particles, and pastes. .
  • a particulate carrier is preferable.
  • the diameter of the particles is from 10 to 500 ⁇ , preferably from 20 to 100.
  • the sustained release can be adjusted by adjusting the degradability of the sustained release carrier.
  • Degradability can be adjusted, for example, by changing the degree of crosslinking during carrier production.
  • the moisture content is 98 to 94%, and it is decomposed and absorbed in 1 to 3 weeks
  • a sustained release carrier may be prepared.
  • the conditions for preparing the tissue engineering material composed of cells and cell growth factors are not particularly limited. For example, they may be simply mixed with each other, or buffer, physiological saline, solvent for injection, Or mixed with a liquid such as a collagen solution Also good.
  • the number of cells to be used is preferably from 100,000 to 500,000.
  • a mixture of cells and cell growth factors can be injected into a scaffold material such as a sponge, mesh, or non-woven fabric molding made of a bioabsorbable material, or used in a state of being mixed with the scaffold material. .
  • the scaffold material used in this case is considered to be essential to be bioabsorbable. In the case of non-absorbability, it is preferable because it physically interferes with tissue regeneration. It is necessary to select and use an appropriate scaffold so that the scaffold material does not interfere with tissue regeneration. If the scaffold material is a synthetic polymer, its absorbency can be controlled by its molecular weight and chemical composition, and if it is a natural polymer, its degree of cross-linking can be controlled. About these methods, a well-known method can be used.
  • a scaffold material used for injection and mixing of cells and cell growth factors used in the present invention it is essential to have a property of being decomposed and absorbed in the living body.
  • Materials used as a carrier for sustained release of cell growth factors can be used.
  • the same material may be used for the scaffold material and the sustained-release carrier, or different materials may be used. Examples of the form include, but are not limited to, a disk shape, a film shape, a rod shape, a particle shape, and a paste shape.
  • the mixture of the cell of the present invention and a cell growth factor or a mixture of the scaffold can be injected into the body by incision through the skin and implantation or injection.
  • the reason for using the mesh is to isolate the implanted collagen sponge site from the kidney tissue site in the tissue, and to clarify whether the regenerated tissue is newly born in the defect, or whether the tissue is derived from the kidney tissue. .
  • Example 2 Isolation and purification of undifferentiated mesenchymal stem cells
  • the particles were washed twice with an aqueous solution of 0.1 wt% Tween 80, 2-propanol and distilled water, and then lyophilized.
  • 100 particles each when dried in air from 2-propanol or in equilibrium swelling at 37 ° C in PBS The water content was calculated as a ratio of the volume of water contained in the particles to the volume of the swollen particles, and the water content was about 95 vol%.
  • the average particle size of the particles during swelling was 40 ⁇ .
  • the cell suspension 50 containing the cells prepared in Example 2 (2 ⁇ 10 4 ) was carefully injected into the collagen scaffold prepared in Example 1 using a syringe equipped with a 22 gauge needle.
  • the scaffold was left for three hours in a C_ ⁇ 2 incubator 37 ° C, cells were fixed in a collagen sponge. Thereafter, the sustained release bFGF-impregnated gelatin particle suspension 50 ⁇ 1 prepared in Example 3 was added.
  • scaffolds were prepared in which only cells or b FGF-impregnated gelatin particles were injected.
  • SD rats were anesthetized with 15 mg / kg phenobarbital per body weight and dissected from the left 11 1 ribs until reaching the abdominal cavity. Exposure while protecting left kidney with gauze I let you. After clamping the renal artery to prevent bleeding, a defect (defect: 5 mm in diameter, 5 mm in depth) was formed in the lateral cortex of the left renal midrenal fistula. A scaffold containing a sustained release body was embedded. The outer skin of the kidney was sewn with 7.0 nylon to prevent detachment. After replacing the kidney, the peritoneal muscle layer and the outer skin were sutured. 3 Six weeks later, the mice were sacrificed with jetyl ether, and the left kidney was collected.
  • a material capable of regenerating the kidney in vivo can be obtained by using a combination of undifferentiated mesenchymal stem cells and cell growth factors. Further, in the present invention, since cells from the self tissue can be used, the problem of immune rejection is solved and it can be said that its utility for medical treatment is very large.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un matériau conçu pour la régénération de rein in vivo. Ce matériau comprend des cellules souches mésenchymateuses non différenciées et un facteur de croissance cellulaire. La présente invention concerne également un procédé de régénération de rein.
PCT/JP2002/007995 2001-08-08 2002-08-06 Materiau de regeneration de rein comprenant des cellules et un facteur de croissance cellulaire WO2003013588A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003518592A JP4358621B2 (ja) 2001-08-08 2002-08-06 細胞と細胞増殖因子とからなる腎臓の再生のための材料

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001240491 2001-08-08
JP2001-240491 2001-08-08

Publications (1)

Publication Number Publication Date
WO2003013588A1 true WO2003013588A1 (fr) 2003-02-20

Family

ID=19071094

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/007995 WO2003013588A1 (fr) 2001-08-08 2002-08-06 Materiau de regeneration de rein comprenant des cellules et un facteur de croissance cellulaire

Country Status (2)

Country Link
JP (1) JP4358621B2 (fr)
WO (1) WO2003013588A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005211477A (ja) * 2004-01-30 2005-08-11 Gunze Ltd 再生医療用支持体
WO2011052089A1 (fr) * 2009-11-02 2011-05-05 ニチバン株式会社 Matériaux vecteurs permettant la libération prolongée in vivo d'un médicament et comprenant un hydrogel réticulé par rayonnement ionisant, et leur procédé de fabrication
US8119397B2 (en) 2004-03-31 2012-02-21 Two Cells Co., Ltd. Therapeutic agents and therapeutic methods for treating injured tissue
US8603462B2 (en) * 2003-04-01 2013-12-10 University Of Utah Research Foundation Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
JP2015160820A (ja) * 2014-02-26 2015-09-07 株式会社Ｃｌｉｏ 慢性腎障害治療のための多能性幹細胞
EP3081226A1 (fr) * 2015-04-14 2016-10-19 Kyoto University Agent pour former un site immunitaire tolérant et agent pour attirer des cellules immunosuppressives
JP2018162308A (ja) * 2018-07-03 2018-10-18 株式会社生命科学インスティテュート 慢性腎障害治療のための多能性幹細胞
JP2021073305A (ja) * 2021-02-09 2021-05-13 株式会社生命科学インスティテュート 慢性腎障害治療のための多能性幹細胞
JPWO2022059236A1 (fr) * 2020-09-17 2022-03-24
US12409191B2 (en) 2012-10-24 2025-09-09 Prokidney Renal cell populations and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08198763A (ja) * 1995-01-31 1996-08-06 Naisemu:Kk 細胞成長因子産生細胞組込み型医療材料
WO1998009582A1 (fr) * 1996-09-05 1998-03-12 Children's Medical Center Corporation Rein prothetique et son utilisation dans le traitement d'affections des reins
WO1999011664A1 (fr) * 1997-09-05 1999-03-11 Genetics Institute, Inc. Cellules genetiquement manipulees qui expriment des proteines morphogenetiques d'os

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08198763A (ja) * 1995-01-31 1996-08-06 Naisemu:Kk 細胞成長因子産生細胞組込み型医療材料
WO1998009582A1 (fr) * 1996-09-05 1998-03-12 Children's Medical Center Corporation Rein prothetique et son utilisation dans le traitement d'affections des reins
WO1999011664A1 (fr) * 1997-09-05 1999-03-11 Genetics Institute, Inc. Cellules genetiquement manipulees qui expriment des proteines morphogenetiques d'os

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IMASAWA T. ET AL.: "The potential of bone marrow-derived cells to differentiate to glomerular mesangial cells", J. AM. SOC. NEPHROL., vol. 12, no. 7, July 2001 (2001-07-01), pages 1401 - 1409, XP002957608 *
TABATA Y. ET AL.: "Bone formation at a rabbit skull defect by autologous bone marrow cells combined with gelatin microspheres containing TGF-beta1", J. BIOMATER. SCI. POLYM. ED., vol. 11, no. 8, 2000, pages 891 - 901, XP002957607 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8603462B2 (en) * 2003-04-01 2013-12-10 University Of Utah Research Foundation Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
JP2005211477A (ja) * 2004-01-30 2005-08-11 Gunze Ltd 再生医療用支持体
US8119397B2 (en) 2004-03-31 2012-02-21 Two Cells Co., Ltd. Therapeutic agents and therapeutic methods for treating injured tissue
WO2011052089A1 (fr) * 2009-11-02 2011-05-05 ニチバン株式会社 Matériaux vecteurs permettant la libération prolongée in vivo d'un médicament et comprenant un hydrogel réticulé par rayonnement ionisant, et leur procédé de fabrication
US12409191B2 (en) 2012-10-24 2025-09-09 Prokidney Renal cell populations and uses thereof
JP2015160820A (ja) * 2014-02-26 2015-09-07 株式会社Ｃｌｉｏ 慢性腎障害治療のための多能性幹細胞
EP3081226A1 (fr) * 2015-04-14 2016-10-19 Kyoto University Agent pour former un site immunitaire tolérant et agent pour attirer des cellules immunosuppressives
JP2018162308A (ja) * 2018-07-03 2018-10-18 株式会社生命科学インスティテュート 慢性腎障害治療のための多能性幹細胞
JPWO2022059236A1 (fr) * 2020-09-17 2022-03-24
JP7691681B2 (ja) 2020-09-17 2025-06-12 コニカミノルタ株式会社 細胞支持体およびその製造方法、細胞の培養方法ならびに細胞構造体
JP2021073305A (ja) * 2021-02-09 2021-05-13 株式会社生命科学インスティテュート 慢性腎障害治療のための多能性幹細胞

Also Published As

Publication number Publication date
JP4358621B2 (ja) 2009-11-04
JPWO2003013588A1 (ja) 2004-11-25

Similar Documents

Publication Publication Date Title
Chowdhury et al. Collagen type I: A versatile biomaterial
Rahmani Del Bakhshayesh et al. Recent advances on biomedical applications of scaffolds in wound healing and dermal tissue engineering
CN103237565B (zh) 用于基于材料的细胞疗法的可注射的成孔水凝胶
CN104984407B (zh) 一种组织工程人工皮肤及其制备方法
CN109943519A (zh) 人工组织前体及制备其的方法
US20020187182A1 (en) Biocompatible fleece for hemostasis and tissue engineering
EP1496824A2 (fr) Composites tissulaires et utilisations
JP7442969B2 (ja) 架橋タンパク質泡を発生するための粉末組成物およびその使用方法
WO2007028169A2 (fr) Procede pour l'implantation cellulaire
WO2014079198A1 (fr) Matériau dégradable de réparation de blessures et son procédé de préparation
JP2003525083A (ja) 創傷治療用作用体
KR20120092632A (ko) 경조직 재생 유도용 재료
JP4358621B2 (ja) 細胞と細胞増殖因子とからなる腎臓の再生のための材料
JPWO2003028782A1 (ja) 生体組織再生用複合材料
WO2002091955A1 (fr) Rein artificiel presentant la fonction de metabolisme de proteine et son procede de fabrication
JP5540301B2 (ja) 多孔質基盤体とその製造方法並びに多孔質基盤体の使用方法
Kimura et al. In situ adipogenesis in fat tissue augmented by collagen scaffold with gelatin microspheres containing basic fibroblast growth factor
Tabata Nanomaterials of drug delivery systems for tissue regeneration
JP2005213449A (ja) ゼラチンスポンジ
JP2005211477A (ja) 再生医療用支持体
CN116531571A (zh) 一种载中药单体的复合凝胶支架及其制备方法和应用
JP2003325652A (ja) 細胞組込型培養皮膚
CN114288463A (zh) 一种流体胶原蛋白止血材料的研制方法
JP2014030663A (ja) 徐放性組織再生材料
Mustafa et al. Chitosan applications used in medical therapy of tissue regeneration

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003518592

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase